Review
Biochemistry & Molecular Biology
Osamu Kumano, Kohei Akatsuchi, Jean Amiral
Summary: Anticoagulant drugs are crucial in preventing and treating thrombosis, but careful evaluation is needed to prevent the risk of bleeding. New generation anticoagulants like DOACs have shown to be effective, but monitoring of their anticoagulant effects may be necessary in certain patients.
Article
Dentistry, Oral Surgery & Medicine
Huda Moutaz Asmael Al-Azzawi, Syed Ameer Hamza, Zichen Lin, Rita Paolini, Michael McCullough, Tami Yap, Antonio Celentano
Summary: Oral squamous cell carcinoma (OSCC) is influenced by components of the coagulation system, and our in vitro studies showed that anticoagulants have anticancer effects on OSCC. A systematic review found limited evidence on murine models investigating the interactions between anticoagulants and oral cancer, highlighting the need for further preclinical research.
Article
Medicine, General & Internal
Arnar B. Ingason, Edward Rumba, Johann P. Hreinsson, Arnar S. Agustsson, Sigrun H. Lund, Daniel A. Palsson, Indridi E. Reynisson, Brynja R. Gudmundsdottir, Pall T. Onundarson, Geir Tryggvason, Einar S. Bjornsson
Summary: This study aims to compare the rates of clinically relevant epistaxis between different oral anticoagulants. The results show that warfarin treatment is associated with higher rates of clinically relevant epistaxis compared to direct oral anticoagulants.
JOURNAL OF INTERNAL MEDICINE
(2022)
Review
Medicine, General & Internal
Youn Kyung Kee, Hee Jung Jeon, Jieun Oh, Tae-Hyun Yoo, Dongwoo Kang, Jungkuk Lee, Dong Ho Shin
Summary: This study demonstrates that DOAC therapy has a better risk-benefit profile than warfarin therapy in patients with AF and CKD. Further well-designed clinical trials are needed to clarify the benefits of DOACs in this patient population.
FRONTIERS IN MEDICINE
(2023)
Article
Medicine, General & Internal
Yu-Ting Wang, Jo-Hsin Chen, Shu-Fen Liao, Yu-Jen Chen, Gregory Y. H. Lip, Jong-Shiuan Yeh
Summary: This study aimed to compare the impact of rivaroxaban, edoxaban, dabigatran, and warfarin on renal outcomes in patients with non-valvular atrial fibrillation. The findings showed that dabigatran was associated with significantly lower risks of declining renal function and cardiac and renal events compared to warfarin, while rivaroxaban and edoxaban did not show protective effects on renal outcomes. Further studies are needed to investigate and compare the impact of renal function between different direct oral anticoagulants in these patients.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2023)
Article
Oncology
Angel Y. S. Wong, Laurie A. Tomlinson, Jeremy P. Brown, William Elson, Alex J. Walker, Anna Schultze, Caroline E. Morton, David Evans, Peter Inglesby, Brian MacKenna, Krishnan Bhaskaran, Christopher T. Rentsch, Emma Powell, Elizabeth Williamson, Richard Croker, Seb Bacon, William Hulme, Chris Bates, Helen J. Curtis, Amir Mehrkar, Jonathan Cockburn, Helen I. McDonald, Rohini Mathur, Kevin Wing, Harriet Forbes, Rosalind M. Eggo, Stephen J. W. Evans, Liam Smeeth, Ben Goldacre, Ian J. Douglas
Summary: This study found a lower risk of COVID-19-related outcomes in patients with non-valvular atrial fibrillation who were using warfarin compared to direct oral anticoagulants (DOACs). Additionally, the study also observed a lower risk of negative control outcomes associated with warfarin.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Jorge L. Reyes, Charles A. Herzog, Heng Yan, Nicholas S. Roetker, James B. Wetmore
Summary: This study aimed to investigate the association between patient and prescriber characteristics and the use of warfarin versus DOACs in patients with AF and CKD. The results showed that DOAC prescriptions, particularly apixaban, increased over time and gradually replaced warfarin. Cardiologists prescribed DOACs more frequently than non-cardiologists.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
(2022)
Article
Cardiac & Cardiovascular Systems
Josephine Harrington, Anthony P. Carnicelli, Kaiyuan Hua, Lars Wallentin, Manesh R. Patel, Stefan H. Hohnloser, Robert P. Giugliano, Keith A. A. Fox, Ziad Hijazi, Renato D. Lopes, Sean D. Pokorney, Hwanhee Hong, Christopher B. Granger
Summary: Through meta-analysis of multiple research databases, it was found that standard-dose DOACs are safer and more effective than warfarin in patients with kidney dysfunction. While lower-dose DOACs do not significantly lower the incidence of bleeding or intracranial hemorrhage compared to standard-dose DOACs, they are associated with a higher incidence of stroke and systemic embolism as well as death. Therefore, these findings support the use of standard-dose DOACs over warfarin in patients with kidney dysfunction.
Article
Urology & Nephrology
Frida Welander, Henrik Renlund, Emoeke Dimeny, Henrik Holmberg, Anders Sjalander
Summary: This Swedish observational study compared the effects of DOAC and well-managed warfarin on stroke and bleeding risk in patients with chronic kidney disease. The study found that DOAC treatment was associated with a 30% lower risk of bleeding compared to warfarin, while the stroke risk was comparable between the two treatments. However, randomized controlled trials are needed to confirm these results.
CLINICAL KIDNEY JOURNAL
(2023)
Review
Dentistry, Oral Surgery & Medicine
Zichen Lin, Li-Qiao R. Ling, Mabel Ng, Laith Matlub, Kunal Mehta, Roshine A. Linus, Mitchell J. Looker, Yovita Melia, Junhan Loong, Rita Paolini, Camile S. Farah, Antonio Celentano
Summary: The study suggests that the use of anticoagulants in oral cancer patients may have beneficial effects on prognosis, but there is a lack of sufficient evidence regarding the interaction between oral squamous cell carcinoma and anticoagulants, necessitating further research.
JOURNAL OF ORAL PATHOLOGY & MEDICINE
(2021)
Review
Pharmacology & Pharmacy
Jerome Roy Semakula, Geraldine Kisa, Johannes P. Mouton, Karen Cohen, Marc Blockman, Munir Pirmohamed, Christine Sekaggya-Wiltshire, Catriona Waitt
Summary: DOACs have been found to be at least as effective as warfarin in preventing stroke in patients with atrial fibrillation and in treating venous thromboembolism. However, the widespread use of DOACs in sub-Saharan Africa is hindered mainly by their higher acquisition costs.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Anthony P. Carnicelli, Hwanhee Hong, Stuart J. Connolly, John Eikelboom, Robert P. Giugliano, David A. Morrow, Manesh R. Patel, Lars Wallentin, John H. Alexander, M. Cecilia Bahit, Alexander P. Benz, Erin A. Bohula, Tze-Fan Chao, Leanne Dyal, Michael Ezekowitz, Keith A.a. Fox, Baris Gencer, Jonathan L. Halperin, Ziad Hijazi, Stefan H. Hohnloser, Kaiyuan Hua, Elaine Hylek, Eri Toda Kato, Julia Kuder, Renato D. Lopes, Kenneth W. Mahaffey, Jonas Oldgren, Jonathan P. Piccini, Christian T. Ruff, Jan Steffel, Daniel Wojdyla, Christopher B. Granger
Summary: DOACs have more favorable efficacy and safety profiles compared to warfarin in patients with atrial fibrillation, showing significant advantages in terms of stroke, systemic embolism, and bleeding.
Article
Cardiac & Cardiovascular Systems
Margaret C. Fang, Alan S. Go, Priya A. Prasad, Jin-Wen Hsu, Dongjie Fan, Cecilia Portugal, Sue Hee Sung, Kristi Reynolds
Summary: Patients with venous thromboembolism who were taking direct oral anticoagulants (DOACs) were on average more satisfied with their anticoagulant treatment compared to those taking warfarin, although the magnitude of the difference was small.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS
(2021)
Article
Cardiac & Cardiovascular Systems
Mateo Porres-Aguilar, Marius M. Hoeper, Belinda N. Rivera-Lebron, Gustavo A. Heresi, Debabrata Mukherjee, Victor F. Tapson
Summary: Patients with chronic thromboembolic pulmonary hypertension (CTEPH) are recommended indefinite anticoagulation therapy, with a recent shift towards direct oral anticoagulants (DOACs) despite lacking safety and efficacy data in this population. Important issues and controversies surrounding the use of DOACs in CTEPH patients need further clinical research exploration.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS
(2021)
Article
Cardiac & Cardiovascular Systems
Chia-Chen Hsu, Cheng-Chi Chen, Chian-Ying Chou, Kuan-Hsuan Chen, Sheng-Fan Wang, Shih-Lin Chang, Yuh-Lih Chang
Summary: In patients with atrial fibrillation and advanced kidney disease, direct oral anticoagulants (DOACs) are more effective and safe than warfarin in preventing stroke/systemic embolism. Among DOACs, apixaban also reduces the risks of any ischemia and any bleeding compared to warfarin.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS
(2023)